



SAFETY DATA SHEET

Revision date: 28-Feb-2015

Version: 3.0

Page 1 of 9

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Pregabalin Oral Solution

Trade Name: LYRICA

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161
Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

EU Classification:

EU Indication of danger: Not classified

Label Elements

Signal Word: Not required

Other Hazards

No data available

Australian Hazard Classification (NOHSC):

Non-Hazardous Substance. Non-Dangerous Goods.

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
------------	------------	-----------------------	-------------------	--------------------	---

SAFETY DATA SHEET

Material Name: Pregabalin Oral Solution
Revision date: 28-Feb-2015

Page 2 of 9
Version: 3.0

3. COMPOSITION / INFORMATION ON INGREDIENTS

Pregabalin	148553-50-8	Not Listed	Repr. Cat. 3;R63	Repr. 2 (H361d)	2.0
------------	-------------	------------	------------------	-----------------	-----

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Propylparaben	94-13-3	202-307-7	Not Listed	Not Listed	*
Methylparaben	99-76-3	202-785-7	Not Listed	Not Listed	*
Sodium phosphate, monobasic	7558-80-7	231-449-2	Not Listed	Not Listed	*
Sodium phosphate, dibasic	7558-79-4	231-448-7	Not Listed	Not Listed	*
Sucralose	56038-13-2	259-952-2	Not Listed	Not Listed	*
Flavor	NOT ASSIGNED	Not Listed	Not Listed	Not Listed	*
Water	7732-18-5	231-791-2	Not Listed	Not Listed	*

Additional Information:

* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Emits toxic fumes of carbon monoxide and oxides of nitrogen.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

SAFETY DATA SHEET

Material Name: Pregabalin Oral Solution
Revision date: 28-Feb-2015

Page 3 of 9
Version: 3.0

Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Refer to Section 12 - Ecological Information, for information on potential effects on the environment. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Pregabalin

Pfizer OEL TWA-8 Hr: 500µg/m³

Analytical Method:

Analytical method available for Pregabalin. Contact Pfizer Inc for further information.

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

SAFETY DATA SHEET

Material Name: Pregabalin Oral Solution
Revision date: 28-Feb-2015

Page 4 of 9
Version: 3.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Solution	Color:	Clear, colorless
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility:	No data available
Water Solubility:	No data available
pH:	No data available.
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Flavor

No data available

Water

No data available

Propylparaben

No data available

Pregabalin

Predicted 7.4 Log D -1.35

Methylparaben

No data available

Sodium phosphate, monobasic

No data available

Sodium phosphate, dibasic

No data available

Sucralose

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: 1.0076 (25 °C)

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition Products: No data available

SAFETY DATA SHEET

Material Name: Pregabalin Oral Solution
Revision date: 28-Feb-2015

Page 5 of 9
Version: 3.0

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information:

The information included in this section describes the potential hazards of the individual ingredients.

Long Term:

Animal studies indicate that this material may cause adverse effects on the fetus

Known Clinical Effects:

Adverse effects most commonly reported in clinical use include dizziness, blurred vision, weight gain, sleepiness (somnolence), inability to concentrate, swelling, and dry mouth. Hypersensitivity reactions may also occur in susceptible individuals. Other less common effects include suicidal behavior.

Acute Toxicity: (Species, Route, End Point, Dose)

Propylparaben

Mouse Oral LD 50 6332 mg/kg
Mouse Sub-tenon injection (eye) LD 50 200 mg/kg

Pregabalin

Rat IV LD50 > 300 mg/kg
Mouse Oral LD50 > 5000mg/kg
Rat Oral LD50 > 5000mg/kg

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Pregabalin

Skin Sensitization - LLNA Rat Negative
Skin Sensitization - Beuhler Guinea Pig Negative

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Propylparaben

3 Week(s) Rat Oral 27.1 g/kg LOAEL Endocrine system
4 Week(s) Rat Oral 347.2 mg/kg LOAEL Male reproductive system

Pregabalin

13 Week(s) Rat Oral 50 mg/kg/day NOAEL Central nervous system, Male reproductive system
4 Week(s) Rat Oral 500 mg/kg/day LOAEL Central Nervous System, Male reproductive system
4 Week(s) Monkey Oral 100 mg/kg/day NOAEL Central Nervous System
52 Week(s) Rat Oral 50 mg/kg/day LOAEL Blood forming organs

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Pregabalin

Peri-/Postnatal Development Rat Oral 100 mg/kg/day NOAEL Developmental toxicity, Fertility
Fertility & Early Embryonic Development - Males Rat Oral 250 mg/kg/day NOAEL No effects at maximum dose
Fertility & Embryonic Development-Females Rat Oral 1250 mg/kg/day NOAEL Negative
Embryo / Fetal Development Rat Oral 500 mg/kg/day NOAEL Not Teratogenic
Embryo / Fetal Development Rabbit Oral 500 mg/kg/day NOAEL Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

SAFETY DATA SHEET

Material Name: Pregabalin Oral Solution
Revision date: 28-Feb-2015

Page 6 of 9
Version: 3.0

11. TOXICOLOGICAL INFORMATION

Pregabalin

Bacterial Mutagenicity (Ames) Bacteria Negative
In Vivo Unscheduled DNA Synthesis Rat Negative
In Vivo Micronucleus Mouse Negative
In Vitro Chromosome Aberration Chinese Hamster Ovary (CHO) cells Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Pregabalin

104 Week(s) Mouse Oral 1000 mg/kg/day NOAEL Not carcinogenic
104 Week(s) Rat Oral 450 mg/kg/day NOAEL Not carcinogenic
104 Week(s) Mouse Oral 200 mg/kg/day NOAEL Malignant tumors

Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.
See below

12. ECOLOGICAL INFORMATION

Environmental Overview:

The environmental characteristics of this mixture have not been fully evaluated. Releases to the environment should be avoided.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Pregabalin

Daphnia magna (Water Flea) EC50 48 Hours > 1000 mg/L
Oncorhynchus mykiss (Rainbow Trout) OECD LC50 96 Hours > 1000 mg/L
Green algae OECD EbC50 72 Hours > 300 mg/L
Green Algae OECD ErC50 72 Hours > 300 mg/L

Aquatic Toxicity Comments:

A greater than symbol (>) indicates that aquatic toxicity was not observed at the maximum dose tested.

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

Pregabalin

Aspergillus niger (Fungus) OECD MIC > 1000 mg/L
Trichoderma viride (Fungus) OECD MIC > 1000 mg/L
Clostridium perfringens (Bacterium) OECD MIC > 997 mg/L
Bacillus subtilis (Bacterium) OECD MIC >1000 mg/L
Nostoc sp. (Freshwater Cyanobacteria) OECD MIC > 1000 mg/L

Persistence and Degradability:

No data available

Bio-accumulative Potential:

Partition Coefficient: (Method, pH, Endpoint, Value)

Pregabalin

Predicted 7.4 Log D -1.35

Mobility in Soil:

No data available

SAFETY DATA SHEET

Material Name: Pregabalin Oral Solution
Revision date: 28-Feb-2015

Page 7 of 9
Version: 3.0

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision A



Propylparaben

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	202-307-7

Methylparaben

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	202-785-7

SAFETY DATA SHEET

Material Name: Pregabalin Oral Solution
Revision date: 28-Feb-2015

Page 8 of 9
Version: 3.0

15. REGULATORY INFORMATION

Sodium phosphate, monobasic

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-449-2

Sodium phosphate, dibasic

CERCLA/SARA 313 Emission reporting	Not Listed
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	5000 lb 2270 kg
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-448-7

Sucralose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	259-952-2

Flavor

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

Water

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2

Pregabalin

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
U.S. Drug Enforcement Administration: Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule V Controlled Substance Schedule 4
EU EINECS/ELINCS List	Not Listed

Additional Information: U.S. Drug Enforcement Agency Controlled Drug Substance, Schedule V

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Reproductive toxicity-Cat.2; H361d - Suspected of damaging the unborn child

SAFETY DATA SHEET

Material Name: Pregabalin Oral Solution
Revision date: 28-Feb-2015

Page 9 of 9
Version: 3.0

Toxic to Reproduction: Category 3

R63 - Possible risk of harm to the unborn child.

Data Sources: Safety data sheets for individual ingredients. Pfizer proprietary drug development information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 16 - Other Information.

Revision date: 28-Feb-2015

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet